Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Commercial Sponsor
Hoffmann-La Roche
Summary
Eligible participants will be assigned to receive either a molecular-guided therapy based on their genomic profile OR a standard chemotherapy (containing Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel), which will be the active comparator to the intervention arm of the trial.